These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7954524)

  • 21. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
    Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
    J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
    J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
    Hess AD; Bright EC
    Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
    Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
    Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The influence of anticancer agents at various stages to induce LAK cell on its cytotoxicity and cell yield. Examination in vitro].
    Baba M
    Nihon Ika Daigaku Zasshi; 1990 Dec; 57(6):531-40. PubMed ID: 2286645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
    Bear HD; McFadden AW; Kostuchenko PJ; Lipshy KA; Hamad GG; Turner AJ; Roberts JD; Carr M; Carr S; Grant S
    Anticancer Drugs; 1996 May; 7(3):299-306. PubMed ID: 8792004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
    Koyama S
    J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
    Nano R; Capelli E; Gerzeli G
    Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways.
    Li H; Wojciechowski W; Dell'Agnola C; Lopez NE; Espinoza-Delgado I
    J Immunol; 2006 Sep; 177(6):3554-63. PubMed ID: 16951314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of murine melanoma with bryostatin 1.
    Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
    Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
    Eckert K; Grünberg E; Immenschuh P; Garbin F; Kreuser ED; Maurer HR
    J Cancer Res Clin Oncol; 1997; 123(8):420-8. PubMed ID: 9292704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of PMA-induced human T cell proliferation by bryostatin is associated with enhanced degradation of conventional protein kinase C (cPKC): Ca2+ signals restore mitogenic activity without abrogating enhanced cPKC degradation.
    Galron D; Tamir A; Altman A; Isakov N
    Cell Immunol; 1994 Oct; 158(1):195-207. PubMed ID: 8087865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.
    Esa AH; Boto WO; Adler WH; May WS; Hess AD
    Int J Immunopharmacol; 1990; 12(5):481-90. PubMed ID: 2210911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
    Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.